Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the nishinihon cooperative study group of adjuvant chemoendocrine therapy for vreast cancer (ACETBC) of Japan

European Journal of Cancer

Volumn 32, Issue 2, 1996, Pages 235-242

  Morimoto, T ^a   Ogawa, M ^b   Orita, K ^c   Sugimachi, K ^d   Toge, T ^e   Dohi, K ^f   Nomura, Y ^g   Monden, Y ^a   Ogawa, N ^h  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

^f HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant therapy; Breast cancer; Ftorafur; PSK; Randomised controlled trial; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; KRESTIN; MITOMYCIN C; TAMOXIFEN; TEGAFUR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANOREXIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; PROTEOGLYCANS; SURVIVAL RATE; TAMOXIFEN; TEGAFUR;

EID: 0029926725     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00579-X     Document Type: Article

References (21)

1. Glick JH, Gelber RD, Goldhirsch HS. Meeting highlights: adjuvant therapy for breast cancer. J Natl Cancer Inst 1992, 84, 1479-1485.
2. Yoshimoto M, Kasumi F, Watanabe S, Fukami A, Nishi M, Kajitani T. Ten-year follow-up results of mitomycin C single agent adjuvant chemotherapy for breast cancer. In Taguchi T, Andrysek O, eds. New Trends in Cancer Chemotherapy with Mitomycin C. Tokyo, Excerpta Medica, 1987, 58-67.
3. Yoshida M, Murai H, Miura H. Chemotherapy with mitomycin-C and cyclophosphamide adjuvant to surgery for breast cancer. Jpn J Clin Oncol 1979, 9, 27-34.
4. Koyama K, Wada T, Takahashi Y, et al. Surgical adjuvant chemotherapy with mitomycin C and cyclophosphamide in Japanese patients with breast cancer. Cancer 1980, 46, 2373-2379.
5. Wada T, Koyama H, Nishizawa Y, et al. Chemo-endocrine therapy for advanced breast cancer - a combined treatment with tamoxifen and FT 207. J Jpn Soc Cancer Ther 1981, 16, 51-55 (in Japanese with English abstract).
6. Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K. Krestin (PSK). Cancer Treat Rev 1984, 11, 131-155.
7. Fugimoto M, Sakai K, Ueda T, Morimoto K, Nakatani S. Results of long-term adjuvant immunochemotherapy after surgery for breast cancer. Proc 14th Int Congr Chemotherapy, Kyoto, 1985, 1326-1327.
8. Japanese Breast Cancer Society. The general rules for clinical and pathological recording of breast cancer. Jpn J Surg 1989, 19, 612-632.
9. Sakamoto G, Sugano H, Hartmann WH. Comparative pathological study of breast cancer among American and Japanese women. Breast Cancer 1981, 4, 211-231.
10. Ansfield FJ, Kallas GJ, Singson JP. Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol 1983, 1, 107-110.
11. Adachi I. Clinical studies on the treatment of patients with advanced breast cancer. Jpn J Cancer Chemother 1981, 21, 72-78 (in Japanese with English abstract).
12. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 1994, 343, 1122-1126.
13. Mitomi T, Tsuchiya S, Iijima N, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 1992, 35, 123-130.
14. Izuo M. Clinicopathological features of recurrent breast cancer. Jpn J Cancer Chemother 1985, 12, 412-420 (in Japanese with English abstract).
15. Boccardo F, Rubagotti A, Bruzzi P, et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multi-centric Italian study. J Clin Oncol 1990, 8, 1310-1320.
16. Goldhirsch A, Gelber RD. Adjuvant chemoendocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig studies III and IV. Recent Results Cancer Res 1989, 115, 153-162.
17. Fisher B, Redmond C, Poisson SL, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990, 8, 1005-1018.
18. Pearson OH, Hubay CA, Gordon NH, et al. Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer. Cancer 1989, 64, 1819-1823.
19. Tomey C. Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial. Recent Results Cancer Res 1989, 96, 153-162.
20. Yasumura T, Oka T, Honjo H, Okada H. Menstrual abnormality in breast cancer patients receiving adjuvant endocrinochemotherapy. Jpn J Cancer Chemother 1988, 15, 2947-2952 (in Japanese with English abstract).
21. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992, 339, 1-15, 71-85.